[
  {
    "ts": "2025-07-01T22:00:05+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts",
    "summary": "Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-rises-market-220005121.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d5ddc0e1-ef59-3e8f-b043-26a7be0ce3a3",
      "content": {
        "id": "d5ddc0e1-ef59-3e8f-b043-26a7be0ce3a3",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.",
        "pubDate": "2025-07-01T22:00:05Z",
        "displayTime": "2025-07-01T22:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
          "originalWidth": 1000,
          "originalHeight": 603,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YgRrCYuBdR1wa08RtjoPHQ--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9.cf.webp",
              "width": 1000,
              "height": 603,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jAWLk_UfDMDSToA2irhEEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-rises-market-220005121.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-rises-market-220005121.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-01T11:34:00+00:00",
    "headline": "Vertex Announces European Commission Approval of ALYFTREK速, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "LONDON, July 01, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK速 (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
    "url": "https://finance.yahoo.com/news/vertex-announces-european-commission-approval-113400322.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "dc0f5795-6842-3f76-a638-128b78c8f229",
      "content": {
        "id": "dc0f5795-6842-3f76-a638-128b78c8f229",
        "contentType": "STORY",
        "title": "Vertex Announces European Commission Approval of ALYFTREK速, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
        "description": "",
        "summary": "LONDON, July 01, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK速 (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
        "pubDate": "2025-07-01T11:34:00Z",
        "displayTime": "2025-07-01T11:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/6bb9ea959aaebbcdea216f5b48bbd354",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TPywxcJfwFs15tPHMQrCQA--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6bb9ea959aaebbcdea216f5b48bbd354.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yUm7UpvXX_IFXid4A49scA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6bb9ea959aaebbcdea216f5b48bbd354.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-european-commission-approval-113400322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-european-commission-approval-113400322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]